CAR T cell therapy in solid tumours

While CAR T cell therapy has been very successful in the past years with regard to hematologic malignancies, the translation to solid tumours remains a challenge.

Now, the results of two trials in the US with mesothelin and claudin 18.2 targeted CAR T cells are very promising and indicate that the therapy can be successfully applied also to solid tumours.

To read more about the results of the trials, read the article published in MedPage Today.